Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 25 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 10406225

    Anti-EphA2 antibodies and methods of use thereof

    The Regents of the University of California · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  2. US 10407485

    Murine anti-NY-ESO-1 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted

  3. US 10391170

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted

  4. US 10363292

    Vaccination with anti-tick antigens to control multiple tick species and disease transmission in white-tailed deer and other host animals

    The United States of America, as represented by the Secretary of Agriculture · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  5. US 10358495

    Anti-LAG3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  6. US 10358487

    Anti-ANGPTL3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  7. US 10351597

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    CAREGEN CO., LTD. · Granted Jul 16, 2019 · Expires Jul 11, 2039

    granted

  8. US 10351598

    Peptide with anti-obesity and anti-diabetic efficacy and use thereof

    CAREGEN CO., LTD. · Granted Jul 16, 2019 · Expires Jul 11, 2039

    granted

  9. US 10342869

    Compositions comprising anti-CD38 antibodies and lenalidomide

    The Regents of the University of California · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted

  10. US 10336824

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

    CytomX Therapeutics, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  11. US 10336833

    Conjugated anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  12. US 10329339

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  13. US 10329338

    Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon

    The Regents of the University of Colorado · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  14. US 10314950

    Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

    The Board of Regents of the University of Texas System · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  15. US 10316105

    Anti-TIE2 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  16. US 10301393

    Methods of treating multiple sclerosis using anti-CD20 antibodies

    VACCINEX, INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted

  17. US 10301380

    Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

    CytomX Therapeutics, Inc. · Granted May 28, 2019 · Expires May 23, 2039

    granted

  18. US 10292971

    Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs

    Olema Pharmaceuticals, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted

  19. US 10287340

    Anti-HIV domain antibodies and method of making and using same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 14, 2019 · Expires May 9, 2039

    granted

  20. US 10285986

    Compounds and anti-tumor NQO1 substrates

    The Board of Regents of the University of Texas System · Granted May 14, 2019 · Expires May 9, 2039

    granted

  21. US 10273307

    Humanized anti-CD134 (OX40) antibodies and uses thereof

    Biocerox Products B.V. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  22. US 10265410

    Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

    HALOZYME, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  23. US 10261095

    Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment

    Julius-Maximilians-Universitat Wurzburg · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  24. US 10259870

    Anti-ANGPTL8 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.